BridgeBio Oncology gains outperform rating from Raymond James

bridgebio-oncology-gains-outperform-rating-from-raymond-james
Wall Street sign in Lower Manhattan, NYC

georgeclerk

  • Raymond James initiated BridgeBio Oncology Therapeutics (BBOT) at outperform, noting the company is well capitalized and has several phase 1 data readouts this year.
  • The firm set a $24 price target (~80% upside based on Jan. 8 close).
  • BridgeBio has